Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27415510 | 0.74 | HSP90AA1 (0.41) | POLBSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL27583944 | 0.74 | — | — | |
| SCHEMBL28364819 | 0.73 | POLB (0.39) | POLBSMN1; SMN2PTPN11RAB9AALDH1A1 | |
| SCHEMBL17277740 | 0.73 | POLB (0.46) | POLBSMN1; SMN2RAB9AALDH1A1NPC1 | |
| SCHEMBL30406742 | 0.73 | POLB (0.46) | POLBSMN1; SMN2RAB9AALDH1A1NPC1 | |
| SCHEMBL31634847 | 0.72 | NFKB1 (0.43) | POLBSMN1; SMN2PTPN11L3MBTL1NFKB1 | |
| SCHEMBL14667045 | 0.72 | NFKB1 (0.43) | POLBSMN1; SMN2PTPN11L3MBTL1NFKB1 | |
| SCHEMBL27992091 | 0.72 | DYRK1A (0.30) | — | |
| SCHEMBL4347552 | 0.72 | CDK4 (0.36) | SMN1; SMN2RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL4350221 | 0.71 | CDK1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005778-B2 | Method for preparing Palbociclib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-06-26 | — | — | US | disclosed |
| US-10005778-B2 | Method for preparing Palbociclib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-06-26 | — | — | US | disclosed |
| US-20170247380-A1 | METHOD FOR PREPARING PALBOCICLIB | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247380-A1 | METHOD FOR PREPARING PALBOCICLIB | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005778-B2 | Method for preparing Palbociclib | CDK2, DCK, PARP1 | POLB 76/4885SMN1; SMN2 3951/4885PTPN11 4679/4885 |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | POLB 422/4885SMN1; SMN2 3957/4885PTPN11 206/4885 |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | CDK4, CCNA1, CCNI | POLB 942/4885SMN1; SMN2 3490/4885PTPN11 1706/4885 |
| US-20170247380-A1 | METHOD FOR PREPARING PALBOCICLIB | CDK2, DCK, PARP1 | POLB 76/4885SMN1; SMN2 3951/4885PTPN11 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.